CRISTIANE DECAT BERGEROT, PhD PSYCHOLOGIST, POSTDOCTORAL FELLOW CITY OF HOPE COMPREHENSIVE CANCER CENTER discusses THE IMPACT OF THE PSYCHOSOCIAL MILIEU…
Browsing: Kidney
Eric A. Singer, MD, MA, MS, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Section of Urologic…
Bellinda King-Kallimanis, PhD of U.S. Food and Drug Administration, Maryland (FDA ) discusses Incorporating Relevant and Meaningful ?Patient-Reported Outcomes in…
André P. Fay, MD, PhD Professor, PUCRS School of Medicine Chief, Medical Oncology Department – Hospital São Lucas da PUCRS/…
Samra Turajlic BA, MBBS, MRCP, PhD, Consultant Medical Oncologist, Royal Marsden NHS Foundation Trust, London Cancer Research UK Clinician Scientist,…
E. Jason Abel MD, FACS University of Wisconsin discusses Cytoreductive nephrectomy Placing recent clinical trials in context at the Seventeenth…
Michael A.S. Jewett DEPARTMENT OF SURGICAL ONCOLOGY PRINCESS MARGARET CANCER CENTRE DIVISION OF UROLOGY THE UNIVERSITY OF TORONTO discusses Heterogeneity…
Kimberly Allman, MSN, CNP Cleveland Clinic Taussig Cancer Institute discusses Ipilimumab plus Nivolumab as Salvage Therapy in Patients with Checkpoint…
Ritesh Kotecha discusses Second-Line VEGFR TKI Outcomes After First-Line Immune Checkpoint Blockade in Metastatic Renal Cell Carcinoma at the Seventeenth…
Neeraj Agarwal Huntsman Cancer Center discusses Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab:?Results of the dose-escalation stage…
Andrey Soares Medical Oncologist Centro Paulista de Oncologia and Hospital Israelita Albert Einstein SPChair LACOG GU gives an UPDATES LATIN…
Rodolfo Borges dos Reis, MD, PhD Uro-oncology Ribeirao Preto Medical School discusses LARCG Latin American Renal Cancer Group at the…
Alberto Diaz de Leon M.D. discusses Whole Body MRI for Detection of Renal Cell Carcinoma Osseous Metastases at the Seventeenth…
Abhishek A. Chakraborty Instructor in Medicine Department of Medical Oncology Laboratory of William Kaelin Dana-Farber Cancer Institute Harvard Medical School…
Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess Medical Center Research Fellow, Dana Farber…
A Ari Hakimi MD Assistant Member, Department of Surgery, Urology Service Member, Immunogenomics and Precision Oncology Platform discusses the Novel…
Toni K. Choueiri, MD Director, Lank Center for Genitourinary Oncology Department of Medical Oncology Dana-Farber Cancer Institute discusses Neovax: From…
Thai H. Ho, MD, PhD Mayo Clinic Arizona discusses Targeting Epigenetics and Chromatin Remodeling Genes From the Seventeenth International Kidney…
Thomas Powles Director of Barts Cancer Centre discusses The next therapeutic targets: TGFbeta From the Seventeenth International Kidney Cancer International…
Abhishek Tripathi MD Assistant Professor of Medicine University of Oklahoma Stephenson Cancer Center discusses Adenosine Pathway Inhibitors From the Seventeenth…
Ranjit S. Bindra, M.D., Ph.D. Associate Professor Departments of Therapeutic Radiology and Experimental Pathology Yale Cancer Center discusses Exploiting oncometabolite-induced…
Suzanne Cole, MD FACP Medical Director, Community Cancer Clinic Richardson Plano UT Southwestern Medical Center discusses Engaging Clinical Trialists in…
Robert G. Uzzo, M.D. Willing G. Pepper Chairman of Surgery Fox Chase Cancer Center Temple University School of Medicine Chair,…
Hyung L. Kim, M.D. Director, Academic Urology Programs Cedars Sinai Medical Center discusses What is the Next Cytoreductive Surgical Trial?…
Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology MD Anderson Cancer Center discusses Combination…
Phillip M. Pierorazio, MD Associate Professor of Urology and Oncology Brady Urological Institute, Department of Urology? Johns Hopkins Medicine, Baltimore,…
Dr. Andrew W. Silagy Urologic Oncology Research Fellow Memorial Sloan Kettering Cancer Center discusses An Evaluation of the Role of…
Nizar M. Tannir University of Texas MD Anderson Cancer Center, Houston, TX, USA discusses CheckMate 214 Retrospective Analyses From the…
Nieves Martinez Chanza Department of Oncology, Jules-Bordet Institute, Free University of Brussels (Belgium) discusses Safety and efficacy of checkpoint inhibitors…
Tian Zhang, MD Assistant Professor of Medicine Duke Cancer Institute discusses PDIGREE From the Seventeenth International Kidney Cancer International Symposium…
Thomas Powles Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, UK…
Rana R. McKay, MD Assistant Professor of Medicine UC San Diego discusses Rationally Targeting the Bone with Radium Plus Cabozantinib…
Matt Campbell MD Assistant Professor GU Medical Oncology UT MD Anderson Cancer Center discusses Ongoing Clinical Trial Update: A Pilot…
Moshe C. Ornstein MD MA, Laura S. Wood RN MSN OCN, Kimberly Allman MSN CNP, Allison Martin PA-C Timothy Gilligan…
Hans Hammers MD, PhD Associate Professor of Internal Medicine in the Division of Hematology-Oncology at UT Southwestern Medical Center discusses…
Charles G. Drake MD / PhD Director GU Medical Oncology Co-Director: Immunotherapy Program Associate Director for Clinical Research Professor of…
Primo N Lara, Jr., MD Director, University of California Davis Comprehensive Cancer Center Professor of Medicine and Executive Associate Dean…
Michael B. Atkins, M.D. William M. Scholl Professor and Vice Chair Department of Oncology Deputy Director Georgetown-Lombardi Comprehensive Cancer Center…
Ewelina Morawa, MD Executive Medical Director CRISPR Therapeutics discusses Allogeneic Anti-CD70 CAR T Cells ?for Renal Cell Carcinoma From the…
Steven L. Chang, MD, MS Assistant Professor of Surgery, Harvard Medical School Surgical Oncologist, Dana-Farber Cancer Institute Associate Surgeon, Division…
Alexander Kutikov, MD, FACS Professor and Chief, Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA discusses Enucleation of Renal Mass:…
Gopal N. Gupta, MD, FACS Associate Professor Departments of Urology, Surgery and Radiology Cardinal Bernardin Cancer Center Loyola University Health…
Steven S. Raman, MD FSAR FSIR Professor of Radiology, Urology and Surgery Division of Abdominal Imaging & Intervention Departments of…
John Leppert, MD MS Associate Professor Stanford University Director of Urologic Oncology, VA Palo Alto discusses Overdiagnosis and the Harms…
Timothy McClure, MD Assistant Professor of Urology Assistant Professor of Interventional Radiology Weill Cornell Medicine discusses Emerging Ablative Technologies -…
Jaime Landman Professor of Urology and Radiology Chairman, Department of Urology UCI discusses Renal mass biopsy in 2018: When, where…
David Braun, MD, PhD, Dana-Farber Cancer Institute discusses Single Cell RNA-Sequencing in RCC from the Seventeenth International Kidney Cancer International…
Dr. Lisa Derosa, MD PhD Candidate Immunoncology – Pr. L. Zitvogel discusses The impact of the stool microbiome in RCC…
James Brugarolas, M.D., Ph.D. Director, Kidney Cancer Program Principal Investigator, UT Southwestern Kidney Cancer SPORE Sherry Wigley Crow Endowed Chair…
James J. Hsieh MD PhD Professor, Molecular Oncology, Siteman Cancer Center, Washington University in St. Louis discusses RCC Profiling from…
Neeraj Agarwal, MD Professor of Medicine Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research Co-Leader, HCI Experimental Therapeutics…
Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of…
Robert Motzer MD, board-certified medical oncologist of Memorial Sloan Kettering Cancer Center, discusses Progress In Advanced Kidney Cancer Treatment At…
Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant…
Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant…
Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant…
Amishi Y. Shah, MD Assistant Professor Genitourinary Medical Oncology MD Anderson Cancer Center Discusses Integrative Medicine & Herbal Supplements. At…
Amishi Y. Shah, MD Assistant Professor Genitourinary Medical Oncology MD Anderson Cancer Center Discusses Immunotherapy Moving To Frontline. At Kidney…
Amishi Y. Shah, MD Assistant Professor Genitourinary Medical Oncology MD Anderson Cancer Center Discusses Gut Microbiome Upcoming Research. At Kidney…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Analyzing Biological…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Kidney Cancer…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Rare Kidney…
Brian Shuch, MD Associate Professor of Urology at UCLA Discusses the Optimal Approach To Small Renal Mass. At Kidney Cancer…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Renal Medullary…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Immunotherapy In…
VITALY MARGULIS MD ASSOCIATE PROFESSOR UROLOGIC ONCOLOGY discusses Why Use Systemic Therapy Before Surgery?. At Kidney Cancer Association National Patient…
VITALY MARGULIS MD ASSOCIATE PROFESSOR UROLOGIC ONCOLOGY discusses Radiotherapy In Kidney Cancer. At Kidney Cancer Association National Patient and Caregiver…
VITALY MARGULIS MD ASSOCIATE PROFESSOR UROLOGIC ONCOLOGY discusses EA8143 PROSPER RCC: Adjuvant Therapy with a Twist. At Kidney Cancer Association…
Chung-Han Lee, MD/PhD Memorial Sloan Kettering Cancer Center Discusses Objective Response Rate, Best Indicator? At Kidney Cancer Association National Patient…
Chung-Han Lee, MD/PhD Memorial Sloan Kettering Cancer Center Discusses Combinations in Kidney Cancer, Who Benefits? At Kidney Cancer Association National…
Chung-Han Lee, MD/PhD Memorial Sloan Kettering Cancer Center Discusses Combination, TKI, Immunotherapy Efficacy. At Kidney Cancer Association National Patient and…
Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology Discusses Von Hippel-Lindau Disease. At Kidney…
Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology Discusses Localized Recurrence Is Rare In…
Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses Sequencing Immunotherapies In Kidney…
Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses Ipilimumab & Nivolumab Combo.…
Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses First Line Therapy In…
Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses Combo Avelumab & Axitinib.…
Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses Combinations In Anti VEGF…
Naomi B Haas MD Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center discusses VEGF Inhibitors In Adjuvant…
Naomi B Haas MD Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center discusses The Allure To The…
Naomi B Haas MD Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center discusses ASSURE, S-TRAC, ATLAS, &…
Susan Demo, Ph.D Calithera Biosciences discusses Only 3% Of Cancer Patients Participate In Clinical Trials at Kidney Cancer Association National…
Mayer Fishman, MD PhD Dept. of GU Oncology Moffitt Cancer Center Dept. of Oncologic Sciences, USF Morsani College of Medicine…
Susan Demo, Ph.D Calithera Biosciences Discusses the Best Way For A Patient To Find A Clinical Trial. At Kidney Cancer…
Matt Campbell MD, MS Assistant Professor Department of Genitourinary Medical Oncology UT MD Anderson Cancer Center Discusses What Does PDL…
Matt Campbell MD, MS Assistant Professor Department of Genitourinary Medical Oncology UT MD Anderson Cancer Center Discusses When Should A…
Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant…
Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of…
Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of…
Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of…
Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of…
Brian Shuch, MD Associate Professor of Urology at UCLA Discusses the Risk Of New Tumor Developing at Kidney Cancer Association…
Brian Shuch, MD Associate Professor of Urology at UCLA Discusses the Treatment Of The Incidental Renal Mass at Kidney Cancer…
E Jason Abel, MD FACS University of Wisconsin School of Medicine and Public Health discusses Surgery in kidney cancer at…
E Jason Abel, MD FACS University of Wisconsin School of Medicine and Public Health Discusses the Higher Risk Of Occurrence…
E Jason Abel, MD FACS University of Wisconsin School of Medicine and Public Health discusses the Complex Surgery Locally Advanced…
Matt Campbell MD, MS Assistant Professor Department of Genitourinary Medical Oncology UT MD Anderson Cancer Center asks the question why…
Mayer Fishman, MD PhD Dept. of GU Oncology Moffitt Cancer Center Dept. of Oncologic Sciences, USF Morsani College of Medicine…
Chung-Han (Joe) Lee, MD/PhD Memorial Sloan Kettering Cancer Center discusses Novel combinational therapies: Is the increased toxicity worth the possibility…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Systemic treatment…
Amishi Y. Shah, MD Assistant Professor Genitourinary Medical Oncology MD Anderson Cancer Center discusses the best agents for second line…
Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses What is the best…
VITALY MARGULIS MD ASSOCIATE PROFESSOR UROLOGIC ONCOLOGY of UT Southwestern discusses NEOADJUVANT THERAPY PRIOR TO SURGERY at the Kidney Cancer…
Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of…
Susan Demo, Ph.D of Calithera discusses Why should I participate in a clinical trial?? Whats in it for me? at…
Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology at MD Anderson discusses What are…
Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant…
Naomi B Haas MD, Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center September 22, 2018 at the…
E Jason Abel, MD FACS University of Wisconsin School of Medicine and Public Health discusses the Management and Outcomes in…
Brian Shuch, MD Associate Professor of Urology Director, Kidney Cancer Program Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research…
Here, Francesco Montorsi, MD, from Vita-Salute San Raffaele University, Milan, Italy, speaks at the 2018 Genitourinary Cancers Symposium, held in…
Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Michael Atkins, MD, of Georgetown University, Washington, DC,…
At the Genitourinary Cancers Symposium 2018 in San Francisco, CA, recent therapeutic developments for renal cell carcinoma (RCC) were discussed…
Michael Atkins, MD, of Georgetown University, Washington DC, outlines the results of the study of VEGF inhibitor axitinib in combination…
Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, gives an overview of a study (NCT02133742) looking at pembrolizumab…
Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Michael Atkins, MD, of Georgetown University, Washington, DC,…
Nataliya Mar, MD, UC Irvine Health, talks about Emerging New Agents for Urothelial Carcinoma | Immunotherapies in Metastatic Castration-Resistant Patients…
Nataliya Mar, MD, UC Irvine Health, talks about Phase 1 Urothelial Carcinoma Data Presented | Combination Therapies in Renal Cell…
In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Robert Figlin,…
Robert Figlin, MD, of Cedars-Sinai Medical Center, Los Angeles, CA, gives an update on the ADAPT trial (NCT01582672), which investigates…
Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reported quality of life on atezolizumab/bevacizumab compared to sunitinib in metastatic…
Dr. Daniel Goldstein discusses the results of a trial of first line pembrolizumab (Keytruda) as first line therapy for patients…
Dr. Daniel Goldstein summarizes the findings of a randomized trial assessing the benefit of adjuvant sunitinib following resection of oligometastatic…
Dr. Daniel Goldstein reviews the key data and limitations from the CARMENA trial that re-evaluated the role of nephrectomy in…
Primo N. Lara, Jr., MD, explains whether the TKIs used in the treatment of renal cell carcinoma (RCC) are interchangeable…
Primo N. Lara, Jr., MD, explains the convenience factor of oral TKIs influences decisions related to advanced renal cell carcinoma…
Exciting new data for metastatic renal cell carcinoma (mRCC) was presented at the American Society of Oncology (ASCO) 2018 Annual…
David I. Quinn, MD,the trade-offs between safety and efficacy in 1st line renal cell carcinoma (RCC) treatment options at the…
Primo N. Lara, Jr., MD, explains the trade-offs between safety and efficacy when considering 1st line renal cell carcinoma (RCC)…
David I. Quinn, MD, discusses whether the convenience factor of oral TKIs enters into the decision-making process when treating advanced…
Primo N. Lara, Jr., MD, explains how a newly diagnosed advanced renal cell carcinoma (RCC) patient should be treated in…
Primo N. Lara, Jr., MD, explains how he decides which metastatic renal cell carcinoma (mRCC) patients should receive a TKI…
David I. Quinn, MD, talks about which metastatic RCC patients should receive a TKI as first-line therapy.
David I. Quinn, MD, explains discusses Keynote 427 for Pembrolizumab, PD-1 Inhibitor and CTLA4 with Nivolumab & Ipilimumab presented at…
Primo N. Lara, Jr., MD, explains how how checkpoint inhibitors figure into treatment algorithms for unresectable 1st line renal cell…
David I. Quinn, MD, shares his thoughts on the most interesting renal cell carcinoma (RCC) data being presented at the…
Jeanny B. Aragon-Ching, MD, FACP, discusses the 2nd line treatment options in RCC after I-O failure at Annual Meeting 2018.
Robert A. Figlin, MD, explains the convenience factor of oral TKIs & treatment decisions in advanced RCC
Robert A. Figlin, MD, explains the trade-offs between safety and efficacy when discussing first-line renal cell carcinoma (RCC) treatment options.
Robert A. Figlin, MD, talks about the best actions to take if newly diagnosed advanced renal cell carcinoma (RCC) patients…
Robert A. Figlin, MD, talks about how checkpoint inhibitors factor into 1st line RCC patient treatments.
Robert A. Figlin, MD, talks about Deciding which metastatic RCC patients should get a TKI as 1st line therapy.
Brian I. Rini, MD, Cleveland Clinic explains Anti-VEGF Therapy Has Been Standard | Field is Changing Dramatically at Annual Meeting…
Brian I. Rini, MD, Cleveland Clinic explains Combinations Being Developed for Kidney Cancer | Efficacy Will Drive Treatment Choices at…
Brian I. Rini, MD, Cleveland Clinic shares Patient Reported Outcomes Measure Tolerabilty | Trial Showed Benefits for Regimen Over Sunitinib…
Brian I. Rini, MD, Cleveland Clinic explains PR Results IMmotion151 Study | Progression-Free Survival & Encouraging Signals at Annual Meeting…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Focus on Potentially Predictive Markers | Neutrophil-to-Lymphocyte Ratio Blood Test May…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Clear Data for Nivolumab & Ipilimumab | In the Frontline for…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains New Combination Strategy for Metastatic RCC | Checkmate-214 Data for Nivolumab…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, Poor-Risk Patients Enrolled in Study for Surgery | Surgery is Not Significantly…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Lacking Data In Current Kidney Cancer Landscape | May Extrapolate Previous…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains CARMENA Trial Randomized Patients | Either Tyrosine-Kinase Inhibitor, or Surgery &…
Saby George, MD, FACP, Roswell Park Cancer Institute, talks about CARMENA Study Showed Sunitnib Alone | Studies Showing Single-Agent Checkpoint…
Saby George, MD, FACP, Roswell Park Cancer Institute, shares CARMENA Study Results | Sunitinib Not Inferior to Sunitinib Following Nephrectomy…
Saby George, MD, FACP, Roswell Park Cancer Institute, explains Checkmate-214 has a Higher Response Rate | 9% of Patients Went…
Saby George, MD, FACP, Roswell Park Cancer Institute, explains Update on Checkmate-214 Study | Approval of Nivolumab & Ipilimumab Combination…
Saby George, MD, FACP, Roswell Park Cancer Institute, shares Checkmate-214 Not for All Kidney Cancer Patients | Study for Advanced…
Ajai Chari, MD, Mt. Sinai discusses Data from MMY1001 Study | Update from Lenalidomide Refractory Subgroup at Annual Meeting 2018
Dr. Jim Brugarolas, Director of the UT Southwestern Kidney Cancer Program, sat down with expert urologist, Dr. Vitaly Margulis, and…